On June 11, Zhendong Pharmaceutical issued an announcement that the ferrous lactate capsule (specification: 0.15g) of Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, was approved, which will have a positive impact on the company's performance.
Iron is a trace element required by the body, iron deficiency and iron deficiency anemia is the main public health problem in China, of which infants, adolescents, women of childbearing age, pregnant women, nursing mothers and some elderly people are the high incidence of iron deficiency anemia. Iron deficiency can cause iron deficiency anemia or various other iron deficiency disorders. Ferrous lactate is widely used clinically as a supplement of iron. It is reported that the ferrous lactate capsules approved by Zhendong Pharmaceutical subsidiary can be used to treat iron deficiency anemia, and only two companies have approved the listing of the capsule dosage form.
Zhendong Pharmaceutical said that the approval of the company's ferrous lactate capsules has enriched the vitamin and mineral product line based on Londi calcium, which will have a positive impact on the company's performance. As of the noon close on June 11, Zhendong Pharmaceutical's stock price rose to 5.15 yuan / share, an increase of 5.97%
(Editor-in-charge: Zhang Qianrong)